Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

AbbVie (NYSE:ABBV) agreed to a three year voluntary drug affordability deal with the US government, paired with a pledge to invest $100b in R&D. The company is expanding its direct to patient drug ...

Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level ...

Numerous genetic studies have identified many risk variants for type 2 diabetes (T2D)—but which genes and proteins are ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Shares of Pfizer Inc. PFE shed 2.42% to $25.86 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.02% to ...

In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

The removal of advanced data from a popular internet resource has proven unpopular – The Athletic breaks down what happened ...

Jan 27 (Reuters) - ‌The ​U.S. ‌Centers for ​Medicare & Medicaid ‍Services on ​Tuesday ​named a ⁠new group of branded drugs ...